American Journal of Ophthalmology
Volume 149, Issue 3 , Pages 513-522 , March 2010

Protective Effect of Paraoxonase 1 Gene Variant Gln192Arg in Age-Related Macular Degeneration

  • Gayle J.T. Pauer

      Affiliations

    • Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Gwen M. Sturgill

      Affiliations

    • Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio
    • ,
  • Neal S. Peachey

      Affiliations

    • Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
    • Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio
    • Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
    • ,
  • Stephanie A. Hagstrom

      Affiliations

    • Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
    • Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
    • Corresponding Author InformationInquiries to Stephanie A. Hagstrom, PhD, Ophthalmic Research - i31, Cole Eye Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195
    • ,
  • Clinical Genomic And Proteomic AMD Study Group

      Affiliations

    • Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
    • Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio
    • Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
    • Department of Ophthalmology, School of Medicine, Case Western Reserve University, Cleveland, Ohio

,Accepted 30 September 2009.

References 

  1. Stone EM. Macular degeneration. Annu Rev Med. 2007;58:477–490
  2. Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res. 2001;20:227–253
  3. Hollman FW, Mulder TJ, Kallan JE. In: Methodology and assumptions for the population projections of the United States: 1999–2100. Washington, D.C: Popul Proj Branch Popul Div, US Census Bureau; 2003;p. 1–34
  4. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572
  5. Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet. 2007;16:174–182
  6. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol. 2006;51:316–363
  7. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385–389
  8. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419–421
  9. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421–424
  10. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7053–7054
  11. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458–462
  12. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553–561
  13. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996;276:1141–1146
  14. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436
  15. Marchegiani F, Marra M, Olivieri F, et al. Paraoxonase 1: genetics and activities during aging. Rejuvenation Res. 2008;11:113–127
  16. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:78–88
  17. Furlong CE, Li W-F, Shih DM, Lusis AJ, Richter RJ, Costa LG. Genetic factors in susceptibility: Serum PON1 variation between individuals and species. Hum Ecol Risk Assess. 2002;8:31–43
  18. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33:498–507
  19. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598–608
  20. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73–76
  21. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme (A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes). J Clin Invest. 1997;99:62–66
  22. Iselius L, Evans DA, Playfer JR. Genetics of plasma paroxonase activity. J Med Genet. 1982;19:424–426
  23. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000;20:516–521
  24. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5_ regulatory-region polymorphisms on paraoxonase gene (PON1) expression. Am J Hum Genet. 2001;68:1428–1436
  25. Deakin S, Leviev I, Brulhart-Meynet MC, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position-107, implicating the Sp1 transcription factor. Biochem J. 2003;372:643–649
  26. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res. 2001;42:528–535
  27. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14:334–336
  28. Ikeda T, Obayashi H, Hasegawa G, et al. Paraoxonase gene polymorphisms and plasma oxidaized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. Am J Ophthalmol. 2001;132:191–195
  29. Baird PN, Chu D, Guida E, Vu HT, Guymer R. Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. Am J Ophthalmol. 2004;138:665–666
  30. Esfandiary H, Chakravarthy U, Patterson C, Young I, Hughes AE. Association study of detoxification genes in age related macular degeneration. Br J Ophthalmol. 2005;89:470–474
  31. Xi Q, Pauer GJ, Traboulsi EI, Hagstrom SA. Mutation screen of the TUB gene in patients with retinitis pigmentosa and Leber congenital amaurosis. Exp Eye Res. 2006;83:569–573
  32. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30:3894–3900
  33. Ferrer-Costa C, Gelpí JL, Zamakola L, Parraga I, de la Cruz X, Orozco M. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics. 2005;21:3176–3178
  34. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115–134
  35. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32
  36. Baskol G, Karakucuk S, Oner AO, et al. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica. 2006;220:12–16
  37. Ates O, Azizi S, Alp HH, et al. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med. 2009;217:17–22
  38. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004;363:689–695
  39. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–1276
  40. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 1999;9:745–753

PII: S0002-9394(09)00737-5

doi: 10.1016/j.ajo.2009.09.024

American Journal of Ophthalmology
Volume 149, Issue 3 , Pages 513-522 , March 2010

Article Tools

* Image Usage & Resolution